Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma

NCT04261855 is registered in ClinicalTrials.gov with Melanoma and Skin Cancer Trials Limited as lead sponsor.

NCT NCT04261855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04261855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of Combination Avelumab With Peptide Receptor Radionuclide Therapy or Conventional Fractionated Radiotherapy in Patients With Metastatic Merkel Cell Carcinoma
Lead sponsor
Melanoma and Skin Cancer Trials Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 8, 2020
Completion date
December 31, 2027
Enrollment
19 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic merkel cell carcinoma